

Global IgA Nephropathy Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GC3B522C8A75EN.html>

Date: February 2023

Pages: 118

Price: US\$ 3,480.00 (Single User License)

ID: GC3B522C8A75EN

Abstracts

Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.

According to our (Global Info Research) latest study, the global IgA Nephropathy Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Conservative treatment is the first-line treatment for patients without rapidly progressive decline in renal function. Specific measures include blood pressure control, use of RAS blockers, treatment of dyslipidemia (statins), low-salt diet (sodium

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of IgA Nephropathy Treatment
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global IgA Nephropathy Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Corticosteroids
 - 1.3.3 Immunosuppressant
 - 1.3.4 ACE and ARB Inhibitors
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global IgA Nephropathy Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Pharmacy
 - 1.4.4 Other
- 1.5 Global IgA Nephropathy Treatment Market Size & Forecast
 - 1.5.1 Global IgA Nephropathy Treatment Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global IgA Nephropathy Treatment Sales Quantity (2018-2029)
 - 1.5.3 Global IgA Nephropathy Treatment Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 AstraZeneca
 - 2.1.1 AstraZeneca Details
 - 2.1.2 AstraZeneca Major Business
 - 2.1.3 AstraZeneca IgA Nephropathy Treatment Product and Services
 - 2.1.4 AstraZeneca IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 AstraZeneca Recent Developments/Updates
- 2.2 Johnson & Johnson Private Limited
 - 2.2.1 Johnson & Johnson Private Limited Details
 - 2.2.2 Johnson & Johnson Private Limited Major Business
 - 2.2.3 Johnson & Johnson Private Limited IgA Nephropathy Treatment Product and Services
 - 2.2.4 Johnson & Johnson Private Limited IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.2.5 Johnson & Johnson Private Limited Recent Developments/Updates
- 2.3 Cipla Inc.
 - 2.3.1 Cipla Inc. Details
 - 2.3.2 Cipla Inc. Major Business
 - 2.3.3 Cipla Inc. IgA Nephropathy Treatment Product and Services
 - 2.3.4 Cipla Inc. IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.3.5 Cipla Inc. Recent Developments/Updates
- 2.4 Hikma Pharmaceuticals PLC
 - 2.4.1 Hikma Pharmaceuticals PLC Details
 - 2.4.2 Hikma Pharmaceuticals PLC Major Business
 - 2.4.3 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Product and Services
 - 2.4.4 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Hikma Pharmaceuticals PLC Recent Developments/Updates
- 2.5 Zydus Cadila
 - 2.5.1 Zydus Cadila Details
 - 2.5.2 Zydus Cadila Major Business
 - 2.5.3 Zydus Cadila IgA Nephropathy Treatment Product and Services
 - 2.5.4 Zydus Cadila IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.5.5 Zydus Cadila Recent Developments/Updates
- 2.6 LEO Pharma A/S
 - 2.6.1 LEO Pharma A/S Details
 - 2.6.2 LEO Pharma A/S Major Business
 - 2.6.3 LEO Pharma A/S IgA Nephropathy Treatment Product and Services
 - 2.6.4 LEO Pharma A/S IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 LEO Pharma A/S Recent Developments/Updates
- 2.7 Fresenius Kabi AG
 - 2.7.1 Fresenius Kabi AG Details
 - 2.7.2 Fresenius Kabi AG Major Business
 - 2.7.3 Fresenius Kabi AG IgA Nephropathy Treatment Product and Services
 - 2.7.4 Fresenius Kabi AG IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Fresenius Kabi AG Recent Developments/Updates
- 2.8 Accord Healthcare
 - 2.8.1 Accord Healthcare Details
 - 2.8.2 Accord Healthcare Major Business

- 2.8.3 Accord Healthcare IgA Nephropathy Treatment Product and Services
- 2.8.4 Accord Healthcare IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 Accord Healthcare Recent Developments/Updates
- 2.9 Abbott
 - 2.9.1 Abbott Details
 - 2.9.2 Abbott Major Business
 - 2.9.3 Abbott IgA Nephropathy Treatment Product and Services
 - 2.9.4 Abbott IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Abbott Recent Developments/Updates
- 2.10 F. Hoffmann-La Roche Ltd.
 - 2.10.1 F. Hoffmann-La Roche Ltd. Details
 - 2.10.2 F. Hoffmann-La Roche Ltd. Major Business
 - 2.10.3 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Product and Services
 - 2.10.4 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
- 2.11 Mylan N.V.
 - 2.11.1 Mylan N.V. Details
 - 2.11.2 Mylan N.V. Major Business
 - 2.11.3 Mylan N.V. IgA Nephropathy Treatment Product and Services
 - 2.11.4 Mylan N.V. IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Mylan N.V. Recent Developments/Updates
- 2.12 Teva Pharmaceutical Industries Ltd.
 - 2.12.1 Teva Pharmaceutical Industries Ltd. Details
 - 2.12.2 Teva Pharmaceutical Industries Ltd. Major Business
 - 2.12.3 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product and Services
 - 2.12.4 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
- 2.13 Sanofi
 - 2.13.1 Sanofi Details
 - 2.13.2 Sanofi Major Business
 - 2.13.3 Sanofi IgA Nephropathy Treatment Product and Services
 - 2.13.4 Sanofi IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.13.5 Sanofi Recent Developments/Updates
- 2.14 Novartis AG
 - 2.14.1 Novartis AG Details
 - 2.14.2 Novartis AG Major Business
 - 2.14.3 Novartis AG IgA Nephropathy Treatment Product and Services
 - 2.14.4 Novartis AG IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.14.5 Novartis AG Recent Developments/Updates
- 2.15 Sun Pharmaceutical Industries Ltd.
 - 2.15.1 Sun Pharmaceutical Industries Ltd. Details
 - 2.15.2 Sun Pharmaceutical Industries Ltd. Major Business
 - 2.15.3 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product and Services
 - 2.15.4 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.15.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
- 2.16 Aurobindo Pharma
 - 2.16.1 Aurobindo Pharma Details
 - 2.16.2 Aurobindo Pharma Major Business
 - 2.16.3 Aurobindo Pharma IgA Nephropathy Treatment Product and Services
 - 2.16.4 Aurobindo Pharma IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.16.5 Aurobindo Pharma Recent Developments/Updates
- 2.17 Lupin
 - 2.17.1 Lupin Details
 - 2.17.2 Lupin Major Business
 - 2.17.3 Lupin IgA Nephropathy Treatment Product and Services
 - 2.17.4 Lupin IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.17.5 Lupin Recent Developments/Updates
- 2.18 Alembic Pharmaceuticals Limited
 - 2.18.1 Alembic Pharmaceuticals Limited Details
 - 2.18.2 Alembic Pharmaceuticals Limited Major Business
 - 2.18.3 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Product and Services
 - 2.18.4 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.18.5 Alembic Pharmaceuticals Limited Recent Developments/Updates
- 2.19 Apotex Inc

- 2.19.1 Apotex Inc Details
- 2.19.2 Apotex Inc Major Business
- 2.19.3 Apotex Inc IgA Nephropathy Treatment Product and Services
- 2.19.4 Apotex Inc IgA Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.19.5 Apotex Inc Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: IGA NEPHROPATHY TREATMENT BY MANUFACTURER

- 3.1 Global IgA Nephropathy Treatment Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global IgA Nephropathy Treatment Revenue by Manufacturer (2018-2023)
- 3.3 Global IgA Nephropathy Treatment Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
 - 3.4.1 Producer Shipments of IgA Nephropathy Treatment by Manufacturer Revenue (\$MM) and Market Share (%): 2022
 - 3.4.2 Top 3 IgA Nephropathy Treatment Manufacturer Market Share in 2022
 - 3.4.2 Top 6 IgA Nephropathy Treatment Manufacturer Market Share in 2022
- 3.5 IgA Nephropathy Treatment Market: Overall Company Footprint Analysis
 - 3.5.1 IgA Nephropathy Treatment Market: Region Footprint
 - 3.5.2 IgA Nephropathy Treatment Market: Company Product Type Footprint
 - 3.5.3 IgA Nephropathy Treatment Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global IgA Nephropathy Treatment Market Size by Region
 - 4.1.1 Global IgA Nephropathy Treatment Sales Quantity by Region (2018-2029)
 - 4.1.2 Global IgA Nephropathy Treatment Consumption Value by Region (2018-2029)
 - 4.1.3 Global IgA Nephropathy Treatment Average Price by Region (2018-2029)
- 4.2 North America IgA Nephropathy Treatment Consumption Value (2018-2029)
- 4.3 Europe IgA Nephropathy Treatment Consumption Value (2018-2029)
- 4.4 Asia-Pacific IgA Nephropathy Treatment Consumption Value (2018-2029)
- 4.5 South America IgA Nephropathy Treatment Consumption Value (2018-2029)
- 4.6 Middle East and Africa IgA Nephropathy Treatment Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

- 5.1 Global IgA Nephropathy Treatment Sales Quantity by Type (2018-2029)
- 5.2 Global IgA Nephropathy Treatment Consumption Value by Type (2018-2029)
- 5.3 Global IgA Nephropathy Treatment Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global IgA Nephropathy Treatment Sales Quantity by Application (2018-2029)
- 6.2 Global IgA Nephropathy Treatment Consumption Value by Application (2018-2029)
- 6.3 Global IgA Nephropathy Treatment Average Price by Application (2018-2029)

7 NORTH AMERICA

- 7.1 North America IgA Nephropathy Treatment Sales Quantity by Type (2018-2029)
- 7.2 North America IgA Nephropathy Treatment Sales Quantity by Application (2018-2029)
- 7.3 North America IgA Nephropathy Treatment Market Size by Country
 - 7.3.1 North America IgA Nephropathy Treatment Sales Quantity by Country (2018-2029)
 - 7.3.2 North America IgA Nephropathy Treatment Consumption Value by Country (2018-2029)
 - 7.3.3 United States Market Size and Forecast (2018-2029)
 - 7.3.4 Canada Market Size and Forecast (2018-2029)
 - 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

- 8.1 Europe IgA Nephropathy Treatment Sales Quantity by Type (2018-2029)
- 8.2 Europe IgA Nephropathy Treatment Sales Quantity by Application (2018-2029)
- 8.3 Europe IgA Nephropathy Treatment Market Size by Country
 - 8.3.1 Europe IgA Nephropathy Treatment Sales Quantity by Country (2018-2029)
 - 8.3.2 Europe IgA Nephropathy Treatment Consumption Value by Country (2018-2029)
 - 8.3.3 Germany Market Size and Forecast (2018-2029)
 - 8.3.4 France Market Size and Forecast (2018-2029)
 - 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
 - 8.3.6 Russia Market Size and Forecast (2018-2029)
 - 8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific IgA Nephropathy Treatment Market Size by Region
 - 9.3.1 Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Region (2018-2029)
 - 9.3.2 Asia-Pacific IgA Nephropathy Treatment Consumption Value by Region (2018-2029)
 - 9.3.3 China Market Size and Forecast (2018-2029)
 - 9.3.4 Japan Market Size and Forecast (2018-2029)
 - 9.3.5 Korea Market Size and Forecast (2018-2029)
 - 9.3.6 India Market Size and Forecast (2018-2029)
 - 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
 - 9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

- 10.1 South America IgA Nephropathy Treatment Sales Quantity by Type (2018-2029)
- 10.2 South America IgA Nephropathy Treatment Sales Quantity by Application (2018-2029)
- 10.3 South America IgA Nephropathy Treatment Market Size by Country
 - 10.3.1 South America IgA Nephropathy Treatment Sales Quantity by Country (2018-2029)
 - 10.3.2 South America IgA Nephropathy Treatment Consumption Value by Country (2018-2029)
 - 10.3.3 Brazil Market Size and Forecast (2018-2029)
 - 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa IgA Nephropathy Treatment Market Size by Country
 - 11.3.1 Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Country (2018-2029)
 - 11.3.2 Middle East & Africa IgA Nephropathy Treatment Consumption Value by Country (2018-2029)
 - 11.3.3 Turkey Market Size and Forecast (2018-2029)

- 11.3.4 Egypt Market Size and Forecast (2018-2029)
- 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
- 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

- 12.1 IgA Nephropathy Treatment Market Drivers
- 12.2 IgA Nephropathy Treatment Market Restraints
- 12.3 IgA Nephropathy Treatment Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
 - 12.5.1 Influence of COVID-19
 - 12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of IgA Nephropathy Treatment and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of IgA Nephropathy Treatment
- 13.3 IgA Nephropathy Treatment Production Process
- 13.4 IgA Nephropathy Treatment Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 IgA Nephropathy Treatment Typical Distributors
- 14.3 IgA Nephropathy Treatment Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global IgA Nephropathy Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global IgA Nephropathy Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 4. AstraZeneca Major Business

Table 5. AstraZeneca IgA Nephropathy Treatment Product and Services

Table 6. AstraZeneca IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. AstraZeneca Recent Developments/Updates

Table 8. Johnson & Johnson Private Limited Basic Information, Manufacturing Base and Competitors

Table 9. Johnson & Johnson Private Limited Major Business

Table 10. Johnson & Johnson Private Limited IgA Nephropathy Treatment Product and Services

Table 11. Johnson & Johnson Private Limited IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. Johnson & Johnson Private Limited Recent Developments/Updates

Table 13. Cipla Inc. Basic Information, Manufacturing Base and Competitors

Table 14. Cipla Inc. Major Business

Table 15. Cipla Inc. IgA Nephropathy Treatment Product and Services

Table 16. Cipla Inc. IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. Cipla Inc. Recent Developments/Updates

Table 18. Hikma Pharmaceuticals PLC Basic Information, Manufacturing Base and Competitors

Table 19. Hikma Pharmaceuticals PLC Major Business

Table 20. Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Product and Services

Table 21. Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Hikma Pharmaceuticals PLC Recent Developments/Updates

Table 23. Zydus Cadila Basic Information, Manufacturing Base and Competitors

Table 24. Zydus Cadila Major Business

Table 25. Zydus Cadila IgA Nephropathy Treatment Product and Services

Table 26. Zydus Cadila IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 27. Zydus Cadila Recent Developments/Updates

Table 28. LEO Pharma A/S Basic Information, Manufacturing Base and Competitors

Table 29. LEO Pharma A/S Major Business

Table 30. LEO Pharma A/S IgA Nephropathy Treatment Product and Services

Table 31. LEO Pharma A/S IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 32. LEO Pharma A/S Recent Developments/Updates

Table 33. Fresenius Kabi AG Basic Information, Manufacturing Base and Competitors

Table 34. Fresenius Kabi AG Major Business

Table 35. Fresenius Kabi AG IgA Nephropathy Treatment Product and Services

Table 36. Fresenius Kabi AG IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 37. Fresenius Kabi AG Recent Developments/Updates

Table 38. Accord Healthcare Basic Information, Manufacturing Base and Competitors

Table 39. Accord Healthcare Major Business

Table 40. Accord Healthcare IgA Nephropathy Treatment Product and Services

Table 41. Accord Healthcare IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 42. Accord Healthcare Recent Developments/Updates

Table 43. Abbott Basic Information, Manufacturing Base and Competitors

Table 44. Abbott Major Business

Table 45. Abbott IgA Nephropathy Treatment Product and Services

Table 46. Abbott IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 47. Abbott Recent Developments/Updates

Table 48. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors

Table 49. F. Hoffmann-La Roche Ltd. Major Business

Table 50. F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Product and Services

Table 51. F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

- Table 52. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
- Table 53. Mylan N.V. Basic Information, Manufacturing Base and Competitors
- Table 54. Mylan N.V. Major Business
- Table 55. Mylan N.V. IgA Nephropathy Treatment Product and Services
- Table 56. Mylan N.V. IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 57. Mylan N.V. Recent Developments/Updates
- Table 58. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
- Table 59. Teva Pharmaceutical Industries Ltd. Major Business
- Table 60. Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product and Services
- Table 61. Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 62. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
- Table 63. Sanofi Basic Information, Manufacturing Base and Competitors
- Table 64. Sanofi Major Business
- Table 65. Sanofi IgA Nephropathy Treatment Product and Services
- Table 66. Sanofi IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 67. Sanofi Recent Developments/Updates
- Table 68. Novartis AG Basic Information, Manufacturing Base and Competitors
- Table 69. Novartis AG Major Business
- Table 70. Novartis AG IgA Nephropathy Treatment Product and Services
- Table 71. Novartis AG IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 72. Novartis AG Recent Developments/Updates
- Table 73. Sun Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
- Table 74. Sun Pharmaceutical Industries Ltd. Major Business
- Table 75. Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product and Services
- Table 76. Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 77. Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
- Table 78. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
- Table 79. Aurobindo Pharma Major Business

Table 80. Aurobindo Pharma IgA Nephropathy Treatment Product and Services

Table 81. Aurobindo Pharma IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 82. Aurobindo Pharma Recent Developments/Updates

Table 83. Lupin Basic Information, Manufacturing Base and Competitors

Table 84. Lupin Major Business

Table 85. Lupin IgA Nephropathy Treatment Product and Services

Table 86. Lupin IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 87. Lupin Recent Developments/Updates

Table 88. Alembic Pharmaceuticals Limited Basic Information, Manufacturing Base and Competitors

Table 89. Alembic Pharmaceuticals Limited Major Business

Table 90. Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Product and Services

Table 91. Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 92. Alembic Pharmaceuticals Limited Recent Developments/Updates

Table 93. Apotex Inc Basic Information, Manufacturing Base and Competitors

Table 94. Apotex Inc Major Business

Table 95. Apotex Inc IgA Nephropathy Treatment Product and Services

Table 96. Apotex Inc IgA Nephropathy Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 97. Apotex Inc Recent Developments/Updates

Table 98. Global IgA Nephropathy Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)

Table 99. Global IgA Nephropathy Treatment Revenue by Manufacturer (2018-2023) & (USD Million)

Table 100. Global IgA Nephropathy Treatment Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 101. Market Position of Manufacturers in IgA Nephropathy Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 102. Head Office and IgA Nephropathy Treatment Production Site of Key Manufacturer

Table 103. IgA Nephropathy Treatment Market: Company Product Type Footprint

Table 104. IgA Nephropathy Treatment Market: Company Product Application Footprint

Table 105. IgA Nephropathy Treatment New Market Entrants and Barriers to Market

Entry

Table 106. IgA Nephropathy Treatment Mergers, Acquisition, Agreements, and Collaborations

Table 107. Global IgA Nephropathy Treatment Sales Quantity by Region (2018-2023) & (K Units)

Table 108. Global IgA Nephropathy Treatment Sales Quantity by Region (2024-2029) & (K Units)

Table 109. Global IgA Nephropathy Treatment Consumption Value by Region (2018-2023) & (USD Million)

Table 110. Global IgA Nephropathy Treatment Consumption Value by Region (2024-2029) & (USD Million)

Table 111. Global IgA Nephropathy Treatment Average Price by Region (2018-2023) & (US\$/Unit)

Table 112. Global IgA Nephropathy Treatment Average Price by Region (2024-2029) & (US\$/Unit)

Table 113. Global IgA Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 114. Global IgA Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 115. Global IgA Nephropathy Treatment Consumption Value by Type (2018-2023) & (USD Million)

Table 116. Global IgA Nephropathy Treatment Consumption Value by Type (2024-2029) & (USD Million)

Table 117. Global IgA Nephropathy Treatment Average Price by Type (2018-2023) & (US\$/Unit)

Table 118. Global IgA Nephropathy Treatment Average Price by Type (2024-2029) & (US\$/Unit)

Table 119. Global IgA Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 120. Global IgA Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 121. Global IgA Nephropathy Treatment Consumption Value by Application (2018-2023) & (USD Million)

Table 122. Global IgA Nephropathy Treatment Consumption Value by Application (2024-2029) & (USD Million)

Table 123. Global IgA Nephropathy Treatment Average Price by Application (2018-2023) & (US\$/Unit)

Table 124. Global IgA Nephropathy Treatment Average Price by Application (2024-2029) & (US\$/Unit)

Table 125. North America IgA Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 126. North America IgA Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 127. North America IgA Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 128. North America IgA Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 129. North America IgA Nephropathy Treatment Sales Quantity by Country (2018-2023) & (K Units)

Table 130. North America IgA Nephropathy Treatment Sales Quantity by Country (2024-2029) & (K Units)

Table 131. North America IgA Nephropathy Treatment Consumption Value by Country (2018-2023) & (USD Million)

Table 132. North America IgA Nephropathy Treatment Consumption Value by Country (2024-2029) & (USD Million)

Table 133. Europe IgA Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 134. Europe IgA Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 135. Europe IgA Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 136. Europe IgA Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 137. Europe IgA Nephropathy Treatment Sales Quantity by Country (2018-2023) & (K Units)

Table 138. Europe IgA Nephropathy Treatment Sales Quantity by Country (2024-2029) & (K Units)

Table 139. Europe IgA Nephropathy Treatment Consumption Value by Country (2018-2023) & (USD Million)

Table 140. Europe IgA Nephropathy Treatment Consumption Value by Country (2024-2029) & (USD Million)

Table 141. Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 142. Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 143. Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 144. Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Application

(2024-2029) & (K Units)

Table 145. Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Region (2018-2023) & (K Units)

Table 146. Asia-Pacific IgA Nephropathy Treatment Sales Quantity by Region (2024-2029) & (K Units)

Table 147. Asia-Pacific IgA Nephropathy Treatment Consumption Value by Region (2018-2023) & (USD Million)

Table 148. Asia-Pacific IgA Nephropathy Treatment Consumption Value by Region (2024-2029) & (USD Million)

Table 149. South America IgA Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 150. South America IgA Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 151. South America IgA Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 152. South America IgA Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 153. South America IgA Nephropathy Treatment Sales Quantity by Country (2018-2023) & (K Units)

Table 154. South America IgA Nephropathy Treatment Sales Quantity by Country (2024-2029) & (K Units)

Table 155. South America IgA Nephropathy Treatment Consumption Value by Country (2018-2023) & (USD Million)

Table 156. South America IgA Nephropathy Treatment Consumption Value by Country (2024-2029) & (USD Million)

Table 157. Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 158. Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 159. Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 160. Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 161. Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Region (2018-2023) & (K Units)

Table 162. Middle East & Africa IgA Nephropathy Treatment Sales Quantity by Region (2024-2029) & (K Units)

Table 163. Middle East & Africa IgA Nephropathy Treatment Consumption Value by Region (2018-2023) & (USD Million)

Table 164. Middle East & Africa IgA Nephropathy Treatment Consumption Value by Region (2024-2029) & (USD Million)

Table 165. IgA Nephropathy Treatment Raw Material

Table 166. Key Manufacturers of IgA Nephropathy Treatment Raw Materials

Table 167. IgA Nephropathy Treatment Typical Distributors

Table 168. IgA Nephropathy Treatment Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. IgA Nephropathy Treatment Picture

Figure 2. Global IgA Nephropathy Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global IgA Nephropathy Treatment Consumption Value Market Share by Type in 2022

Figure 4. Corticosteroids Examples

Figure 5. Immunosuppressant Examples

Figure 6. ACE and ARB Inhibitors Examples

Figure 7. Global IgA Nephropathy Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 8. Global IgA Nephropathy Treatment Consumption Value Market Share by Application in 2022

Figure 9. Hospital Examples

Figure 10. Pharmacy Examples

Figure 11. Other Examples

Figure 12. Global IgA Nephropathy Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 13. Global IgA Nephropathy Treatment Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 14. Global IgA Nephropathy Treatment Sales Quantity (2018-2029) & (K Units)

Figure 15. Global IgA Nephropathy Treatment Average Price (2018-2029) & (US\$/Unit)

Figure 16. Global IgA Nephropathy Treatment Sales Quantity Market Share by Manufacturer in 2022

Figure 17. Global IgA Nephropathy Treatment Consumption Value Market Share by Manufacturer in 2022

Figure 18. Producer Shipments of IgA Nephropathy Treatment by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021

Figure 19. Top 3 IgA Nephropathy Treatment Manufacturer (Consumption Value) Market Share in 2022

Figure 20. Top 6 IgA Nephropathy Treatment Manufacturer (Consumption Value) Market Share in 2022

Figure 21. Global IgA Nephropathy Treatment Sales Quantity Market Share by Region (2018-2029)

Figure 22. Global IgA Nephropathy Treatment Consumption Value Market Share by Region (2018-2029)

Figure 23. North America IgA Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)

Figure 24. Europe IgA Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)

Figure 25. Asia-Pacific IgA Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)

Figure 26. South America IgA Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)

Figure 27. Middle East & Africa IgA Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)

Figure 28. Global IgA Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 29. Global IgA Nephropathy Treatment Consumption Value Market Share by Type (2018-2029)

Figure 30. Global IgA Nephropathy Treatment Average Price by Type (2018-2029) & (US\$/Unit)

Figure 31. Global IgA Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 32. Global IgA Nephropathy Treatment Consumption Value Market Share by Application (2018-2029)

Figure 33. Global IgA Nephropathy Treatment Average Price by Application (2018-2029) & (US\$/Unit)

Figure 34. North America IgA Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 35. North America IgA Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 36. North America IgA Nephropathy Treatment Sales Quantity Market Share by Country (2018-2029)

Figure 37. North America IgA Nephropathy Treatment Consumption Value Market Share by Country (2018-2029)

Figure 38. United States IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Canada IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Mexico IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 41. Europe IgA Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 42. Europe IgA Nephropathy Treatment Sales Quantity Market Share by

Application (2018-2029)

Figure 43. Europe IgA Nephropathy Treatment Sales Quantity Market Share by Country (2018-2029)

Figure 44. Europe IgA Nephropathy Treatment Consumption Value Market Share by Country (2018-2029)

Figure 45. Germany IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. France IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. United Kingdom IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Russia IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Italy IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. Asia-Pacific IgA Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 51. Asia-Pacific IgA Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 52. Asia-Pacific IgA Nephropathy Treatment Sales Quantity Market Share by Region (2018-2029)

Figure 53. Asia-Pacific IgA Nephropathy Treatment Consumption Value Market Share by Region (2018-2029)

Figure 54. China IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. Japan IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. Korea IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. India IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Southeast Asia IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. Australia IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. South America IgA Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 61. South America IgA Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)

- Figure 62. South America IgA Nephropathy Treatment Sales Quantity Market Share by Country (2018-2029)
- Figure 63. South America IgA Nephropathy Treatment Consumption Value Market Share by Country (2018-2029)
- Figure 64. Brazil IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 65. Argentina IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 66. Middle East & Africa IgA Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
- Figure 67. Middle East & Africa IgA Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
- Figure 68. Middle East & Africa IgA Nephropathy Treatment Sales Quantity Market Share by Region (2018-2029)
- Figure 69. Middle East & Africa IgA Nephropathy Treatment Consumption Value Market Share by Region (2018-2029)
- Figure 70. Turkey IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 71. Egypt IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 72. Saudi Arabia IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 73. South Africa IgA Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 74. IgA Nephropathy Treatment Market Drivers
- Figure 75. IgA Nephropathy Treatment Market Restraints
- Figure 76. IgA Nephropathy Treatment Market Trends
- Figure 77. Porters Five Forces Analysis
- Figure 78. Manufacturing Cost Structure Analysis of IgA Nephropathy Treatment in 2022
- Figure 79. Manufacturing Process Analysis of IgA Nephropathy Treatment
- Figure 80. IgA Nephropathy Treatment Industrial Chain
- Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
- Figure 82. Direct Channel Pros & Cons
- Figure 83. Indirect Channel Pros & Cons
- Figure 84. Methodology
- Figure 85. Research Process and Data Source

I would like to order

Product name: Global IgA Nephropathy Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GC3B522C8A75EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC3B522C8A75EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

